VEGF stimulation enhances Livin protein synthesis through mTOR signaling

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Signaling

Background:

• Livin, an inhibitor of apoptosis protein (IAP), is overexpressed in various cancers, contributing to tumor cell survival.
• The precise molecular mechanisms regulating Livin expression in tumors remain incompletely understood.
• Targeting Livin represents a potential therapeutic strategy for cancer treatment.

Purpose of the Study:

• To elucidate the molecular mechanism controlling Livin expression under vascular endothelial growth factor (VEGF) stimulation.
• To investigate the role of the mTOR signaling pathway in VEGF-induced Livin translation.
• To evaluate the therapeutic potential of inhibiting the VEGF/mTOR/Livin signaling axis.

Main Methods:

• Stimulation of HeLa and SK-MEL-28 cells with VEGF.
• Analysis of Livin protein and mRNA expression levels.
• Assessment of mTOR signaling pathway activation, including 4E-BP1 phosphorylation.
• Evaluation of cell viability following Livin silencing or treatment with Rapamycin and cytotoxic agents.

Main Results:

• VEGF stimulation increased Livin protein levels in cancer cells without altering gene transcription or mRNA levels.
• VEGF activated the mTOR signaling pathway, leading to 4E-BP1 phosphorylation and enhanced Livin translation initiation.
• Livin silencing or inhibition of the mTOR pathway with Rapamycin reduced Livin protein levels and decreased cancer cell viability.
• Combination therapy involving Rapamycin and cytotoxic agents further enhanced cell death.

Conclusions:

• VEGF promotes cancer cell survival by upregulating Livin translation through the mTOR/4E-BP1 pathway.
• Ablation of Livin translation effectively removes an anti-apoptotic mechanism crucial for aggressive tumor behavior.
• Pharmacologic inhibition of the VEGF/mTOR/Livin signaling cascade presents a promising novel therapeutic strategy for cancer treatment.